Key result
A competitive electrophoretic mobility shift assay using a digoxigenin-labeled probe detects nucleotide-protein interactions in vitro, avoiding the safety issues of radioactive probes.
Why the study?
Traditional EMSA approaches have safety issues and limitations due to the short lifespan of 32P-radiolabeled DNA probes.
Describes a non-radioactive competitive EMSA protocol using DIG-labeled probes for detecting nucleotide-protein interactions in vitro.
Supports safer non-radioactive EMSA in research; leaves open clinical translation in cardiology.
Electrophoretic mobility shift assay (EMSA) is a classical and popular approach for DNA/RNA protein-binding affinity detection in vitro. This protocol describes a competitive EMSA assay using digoxigenin (DIG)-labeled probe, which solves the safety issues and limitations attributed to the short lifespan of the 32P-radiolabeled DNA probe. We detail steps for DNA probe preparation, protein-DNA mixture coincubation, EMSA, and competitive EMSA process. We optimize the standard DIG-ddUTP-labeling EMSA protocol to high sensitivity with reproducible results. For complete details on the use and execution of this protocol, please refer to Feng et al. (2022).
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) studied this question. Digoxigenin (DIG)-labeled probe competitive EMSA was evaluated. A competitive electrophoretic mobility shift assay using a digoxigenin-labeled probe detects nucleotide-protein interactions in vitro, avoiding the safety issues of radioactive probes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: